Celgene Corporation, Dana-Farber Cancer Institute & University of Arkansas for Medical Sciences Establish the Myeloma Genome ...
December 03 2016 - 5:30PM
Business Wire
Project will create the largest dataset of
molecular profiling for patients with multiple myeloma leading to
tests that could improve diagnosis, prognosis and new
treatments
Celgene Corporation (NASDAQ:CELG), Dana-Farber Cancer Institute
and the University of Arkansas for Medical Sciences today announced
the creation of the Myeloma Genome Project, a collaborative
initiative aimed at compiling the largest dataset of high-quality
genomic and clinical data to identify distinct molecular disease
segments within multiple myeloma to advance diagnosis, prognosis
and treatment of multiple myeloma patients. The initiative seeks to
develop clinically relevant tests. Details of the project and
initial characterization and preliminary analyses of newly
diagnosed myeloma patient data were presented today by Brian
Walker, Ph.D., of the University of Arkansas for Medical Sciences
at the 58th American Society of Hematology Annual Meeting in San
Diego, Calif.
“The Myeloma Genome Project is a really exciting initiative that
may change the way we manage myeloma patients,” said Gareth Morgan,
M.D., Ph.D., Director of the Myeloma Institute at the University of
Arkansas for Medical Sciences.
Current technologies have discovered five major translocation
groups within myeloma patients and these mutations have
demonstrated varying effects on prognosis. The Myeloma Genome
Project is also looking at minor translocation and mutational
groups that are often poorly described due to small sample numbers
in limited data sets. The group has established a set of 2,161
patients for which whole exome sequencing (WES; n=1,436), whole
genome sequencing (WGS; n=708), targeted panel sequencing (n=993)
and expression data from RNA-sequencing and gene expression arrays
(n=1,497) were available. The data were collected from the Myeloma
XI trial (UK), Intergroupe Francophone du Myeloma/Dana-Farber
Cancer Institute, Myeloma Institute at the University of Arkansas
for Medical Sciences and the Multiple Myeloma Research
Foundation.
“Understanding the various subgroups within multiple myeloma
that exhibit distinct pathogenesis and clinical behavior is
critical when looking to advance new therapies, particularly when
considering a targeted approach,” said Rob Hershberg, M.D., Ph.D.,
Executive Vice President and Chief Scientific Officer at Celgene.
“We look forward to the insights that this collaboration will
provide for research and for patients.”
“The Myeloma Genome Project expects to lead the way towards
developing personalized and targeted therapy to improve patient
outcomes in myeloma,” said Nikhil Munshi, M.D., Director of Basic
and Correlative Science at the Jerome Lipper Multiple Myeloma
Center at Dana-Farber Cancer Institute.
The Myeloma Genome Project has begun to integrate these diverse,
large genomic data sets and is identifying genetic information that
may inform clinical targets for therapy. While analyses are not
completed, the current efforts clearly demonstrate the feasibility
of this approach and the project leaders plan to expand
collaboration to include additional investigators and institutions
and present updates at future medical and scientific meetings
including publications in peer-reviewed journals.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
About Dana-Farber Cancer Institute
From achieving the first remissions in childhood cancer with
chemotherapy in 1948, to developing the very latest new therapies,
Dana-Farber Cancer Institute is one of the world’s leading centers
of cancer research and treatment. It is the only center ranked in
the top 4 of U.S. News and World Report’s Best Hospitals for both
adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative
efforts to reduce the burden of cancer through scientific inquiry,
clinical care, education, community engagement, and advocacy.
Dana-Farber/Brigham and Women’s Cancer Center provides the latest
in cancer care for adults; Dana-Farber/Boston Children's Cancer and
Blood Disorders Center for children. The Dana-Farber/Harvard Cancer
Center unites the cancer research efforts of five Harvard academic
medical centers and two graduate schools, while Dana-Farber
Community Cancer Care provides high quality cancer treatment in
communities outside Boston’s Longwood Medical Area.
Dana-Farber is dedicated to a unique, 50/50 balance between
cancer research and care, and much of the Institute’s work is
dedicated to translating the results of its discovery into new
treatments for patients locally and around the world.
About the University of Arkansas for Medical Sciences
The University of Arkansas for Medical Sciences (UAMS) is
Arkansas’ only comprehensive academic health center, with colleges
of Medicine, Nursing, Pharmacy, Health Professions and Public
Health; a graduate school; a hospital; a northwest Arkansas
regional campus; a statewide network of regional centers; and seven
institutes: the Winthrop P. Rockefeller Cancer Institute, the
Jackson T. Stephens Spine & Neurosciences Institute, the
Myeloma Institute, the Harvey & Bernice Jones Eye Institute,
the Psychiatric Research Institute, the Donald W. Reynolds
Institute on Aging and the Translational Research Institute. It is
the only adult Level 1 trauma center in Arkansas. UAMS physicians
and other professionals provide care to patients at UAMS, Arkansas
Children’s Hospital, the VA Medical Center and UAMS regional
centers throughout the state. The UAMS Myeloma Institute is the
most comprehensive center in the world for research and clinical
care related to multiple myeloma and related diseases, such
as Castleman Disease and Waldenstrom
Macroglobulemia. The institute’s team of scientists and
clinicians has pioneered many advances that have become standards
of care, leading to improved survival rates. The UAMS Myeloma
Institute is known for its “bench to bedside” approach, continually
translating advances in the laboratory into breakthrough clinical
treatments.
Visit www.uams.edu or www.uamshealth.com. Find us on Facebook,
Twitter, YouTube or Instagram.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161203005056/en/
Media:For Celgene:Greg Geissman, +1-908-673-9854Senior Director,
Corporate Affairs Communicationsggeissman@celgene.comorFor
UAMS:Leslie Taylor, +1-501-951-7260Vice Chancellor, Communications
& Marketingleslie@uams.eduorFor DFCI:Ellen Berlin,
+1-617-632-5357Director, Media
RelationsEllen_Berlin@DFCI.HARVARD.EDU
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024